Model N (MODN) Q1 Earnings Miss Despite Higher Revenues

Model N (MODN) Q1 Earnings Miss Despite Higher Revenues

Model N, Inc. MODN delivered mixed first-quarter fiscal 2024 results, with the top line beating the Zacks Consensus Estimate but the bottom line missing the same. The San Mateo, CA-based company recorded a top-line expansion year over year, driven by strong momentum in all business verticals.

Net Income

On a GAAP basis, the company incurred a net loss of $1.8 million or a loss of 5 cents per share compared with a loss of $4.1 million or a loss of 11 cents per share in the year-ago quarter. Net sales growth year over year led to a narrower loss during the quarter.

Non-GAAP net income rose to $10.9 million or 28 cents per share from $8.7 million or 22 cents per share in the year-earlier quarter. The bottom line missed the Zacks Consensus Estimate by a penny.

Model N, Inc. Price, Consensus and EPS Surprise

Model N, Inc. price-consensus-eps-surprise-chart | Model N, Inc. Quote

Revenues

The company generated $63.5 million in revenues, up 7% year over year. New logo signings, strong renewals and customer base expansions drove the top line. The top line surpassed the Zacks Consensus Estimate of $62 million.

Net sales from Subscription rose to $47.7 million, up from $44.2 million in the prior-year quarter. The figure surpassed our estimate of $46.9 million. SaaS ARR (annual recurring revenue) improved 16% year over year to $134.8 million.

In High Tech business, Taiwan Semiconductor deployed Model N’s channel data management and revenue cloud to automate various key processes. A prominent manufacturer of power conversion, measurement and control solutions also selected Model N’s solution during the quarter. These developments supported the top line in this vertical.

In business services, the company witnessed solid momentum. United Therapeutics utilizes the newly launched State Price Transparency Management business services offering. Moderna also extended usage of MODN’s business services to better manage their membership, contract administration and rebate processing.

In Life Sciences, Model N continues to see healthy demand among its existing customer base, backed by new product launches. Novartis utilized Model N Engage to enhance operational excellence. A global biopharmaceutical company, Apellis Pharmaceuticals, also selected MODN’s Global Launch Excellence solution during the quarter.

Professional Services revenues totaled $15.8 million, up from $14.9 million a year ago, driven by growing demand for the company’s mission-critical solutions. The top line beat our estimate of $15.1 million.

Other Details

Non-GAAP gross profit increased to $38.3 million from $36.1 million a year ago, with respective margins of 60.3% and 61%. Adjusted EBITDA was $9.9 million, up from $9.1 million in the prior-year quarter. Non-GAAP operating income stood at $9.6 million compared with $8.9 million in the year-earlier quarter.